Clinical evaluation of the effect for prophylactic balloon occlusion in pregnancies complicated with placenta accreta spectrum disorder: A systematic review and meta-analysis
- PMID: 38899567
- DOI: 10.1002/ijgo.15704
Clinical evaluation of the effect for prophylactic balloon occlusion in pregnancies complicated with placenta accreta spectrum disorder: A systematic review and meta-analysis
Abstract
Background: Placenta accreta spectrum (PAS) disorder is a critical and severe obstetric condition associated with high risk of intraoperative massive hemorrhage and cesarean hysterectomy. Severe obstetric hemorrhage is currently one of the leading causes of maternal death worldwide. Prophylactic balloon occlusions, including prophylactic balloon occlusion of the abdominal aorta (PBOAA) and prophylactic balloon occlusion of the internal iliac arteries (PBOIIA), are the most common means of controlling hemorrhage in patients with PAS disorder, but their effectiveness is still debated.
Objective: A systematic review and meta-analysis were conducted to evaluate the clinical effectiveness of prophylactic balloon occlusion during cesarean section (CS) in improving maternal outcomes for PAS patients.
Search strategy: MEDLINE, EMBASE, OVID, PubMed and the Cochrane Library were systematically searched from the inception dates to June 2022, using the keywords "placenta accreta spectrum disorder/morbidly adherent placenta (placenta previa, placenta accreta, placenta increta, placenta percreta), balloon occlusion, internal iliac arteries, abdominal aorta, hemorrhage, hysterectomy, estimated blood loss (EBL), packed red blood cells (PRBCs)" to identify the systematic reviews or meta-analyses.
Selection criteria: All articles regarding PAS disorders and including the application of balloon occlusion were included in the screening.
Data collection and analysis: Two independent researchers performed the data extraction and assessed study quality. EBL volume and PRBC transfusion volume was regarded as the primary endpoints. Random and fixed effects models were used for the meta-analysis (RRs and 95% CIs), and the Newcastle-Ottawa Scale was used for quality assessments.
Main results: Of 429 studies identified, a total of 35 trials involving the application of balloon occlusion for patients with PAS disorder during CS were included. A total of 19 studies involving 935 patients who underwent PBOIIA were included in the PBOIIA group, and 851 patients were included in control 1 group. Ten studies including 428 patients with PAS who underwent PBOAA were allocated to the PBOAA group, and 324 patients without PBOAA were included in control 2 group. Simultaneously, we compared the effect on PBOAA and PBOIIA including seven studies, which referred to 267 cases in the PBOAA group and 313 cases in the PBOIIA group. The results showed that the PBOIIA group had a reduced EBL volume (MD: 342.06 mL, 95% CI: -509.90 to -174.23 mL, I2 = 77%, P < 0.0001) and PRBC volume (MD: -1.57 U, 95% CI: -2.49 to -0.66 U, I2 = 91%, P = 0.0008) than that in control 1 group. With regard to the EBL volume (MD: -926.42 mL, 95% CI: -1437.07 to -415.77 mL, I2 = 96%, P = 0.0004) and PRBC transfusion volume (MD: -2.42 U, 95% CI: -4.25 to -0.59 U, I2 = 99%, P = 0.009) we found significant differences between the PBOAA group and control 2 group. Prophylactic balloon occlusion (PBOAA and PBOIIA) had a significant effect on reducing intraoperative blood loss and blood transfusion volume in patients with PAS. Moreover, PBOAA was more effective than PBOIIA in reducing intraoperative blood loss (MD: -406.63 mL, 95% CI: -754.12 to -59.13 mL, I2 = 92%, P = 0.020), but no significant difference in controlling PRBCs (MD: -3.48 U, 95% CI: -8.90 to 1.95 U, I2 = 99%, P = 0.210) between the PBOIIA group and the PBOAA group. Hierarchical analysis was conducted by differentiating gestational weeks and maternal age to reduce the high heterogeneity of meta-analysis. Hierarchical analysis results demonstrated the heterogeneities of the study were reduced to some extent, and gestational weeks and maternal age might be the cause of increased heterogeneity.
Conclusion: Prophylactic balloon occlusion is a safe and effective method to control hemorrhage and reduce PRBC transfusion volume for patients with PAS, and PBOAA could reduce more intraoperative blood loss than PBOIIA. However, we found no statistical difference in lessening packed red blood cell transfusion volume for PAS patients. Hence, preoperative prophylactic balloon occlusion is the recommended application for PAS patients in obstetric CSs. Furthermore, PBOAA is preferred for controlling intraoperative bleeding in patients with corresponding medical conditions.
Keywords: abdominal aorta; balloon occlusion; hemorrhage; internal iliac arteries; placenta accreta spectrum.
© 2024 International Federation of Gynecology and Obstetrics.
Similar articles
-
The effect of prophylactic balloon occlusion in patients with placenta accreta spectrum: a Bayesian network meta-analysis.Eur Radiol. 2022 May;32(5):3297-3308. doi: 10.1007/s00330-021-08423-6. Epub 2021 Nov 30. Eur Radiol. 2022. PMID: 34846565 Review.
-
Effect of prophylactic balloon occlusion of internal iliac artery in pregnancies complicated by placenta previa and accreta.BMC Pregnancy Childbirth. 2021 Sep 21;21(1):640. doi: 10.1186/s12884-021-04103-x. BMC Pregnancy Childbirth. 2021. PMID: 34548060 Free PMC article.
-
Endovascular interventional modalities for haemorrhage control in abnormal placental implantation deliveries: a systematic review and meta-analysis.Eur Radiol. 2018 Jul;28(7):2713-2726. doi: 10.1007/s00330-017-5222-0. Epub 2018 Feb 5. Eur Radiol. 2018. PMID: 29404775
-
Risk factors of MRI findings for predicting patient outcomes of placenta accreta spectrum and placenta previa after prophylactic balloon occlusion of the internal iliac artery.Eur J Obstet Gynecol Reprod Biol. 2023 Mar;282:31-37. doi: 10.1016/j.ejogrb.2023.01.001. Epub 2023 Jan 2. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 36630816
-
The effect prophylactic internal iliac artery balloon occlusion in patients with placenta previa or placental accreta spectrum: a systematic review and meta-analysis.Reprod Biol Endocrinol. 2021 Mar 4;19(1):40. doi: 10.1186/s12958-021-00722-3. Reprod Biol Endocrinol. 2021. PMID: 33663536 Free PMC article.
Cited by
-
Prophylactic internal iliac artery balloon occlusion in the management of placenta accreta spectrum disorders: a meta-analysis.Rev Bras Ginecol Obstet. 2025 May 4;47:e-rbgo19. doi: 10.61622/rbgo/2025rbgo19. eCollection 2025. Rev Bras Ginecol Obstet. 2025. PMID: 40535423 Free PMC article.
References
REFERENCES
-
- Silver RM. Abnormal placentation: placenta previa, vasa previa, and placenta accreta. Obstet Gynecol. 2015;126(3):654‐668. doi:10.1097/AOG.0000000000001005
-
- Jauniaux E, Chantraine F, Silver RM, Langhoff‐Roos J, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: epidemiology. Int J Gynaecol Obstet. 2018;140(3):265‐273. doi:10.1002/ijgo.12407
-
- Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066‐1074. doi:10.1016/S0140-6736(06)68397-9
-
- Jauniaux E, Alfirevic Z, Bhide AG, et al. Royal College of Obstetricians and Gynaecologists. placenta praevia and placenta accreta: diagnosis and management: green‐top guideline no. 27a. BJOG. 2019;126(1):e1‐e48. doi:10.1111/1471-0528.15306
-
- Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta‐prevalence, risk factors and antenatal suspicion: results from a large population‐based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348‐1355. doi:10.1111/1471-0528.13547
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical